T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.

Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F
Front Immunol. 2023 Feb 16;14:1063838. doi: 10.3389/fimmu.2023.1063838. eCollection 2023. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.